Aidoc is advancing its generative AI tool, First Read, towards FDA approval, highlighting its potential to transform radiology diagnostics.
In June, the FDA granted Aidoc a breakthrough designation for First Read, a generative AI tool designed to analyze chest X-rays and produce reports for radiologists. This designation allows for expedited review, reflecting the FDA's ongoing exploration of generative AI applications in medical devices. Aidoc's system aims to identify over 100 diseases, providing a comprehensive diagnostic output that integrates detection and reporting in a single process.
CEO Elad Walach emphasized the importance of achieving high safety and accuracy standards, noting that the development process involves extensive training and validation of AI models. With over $300 million raised for model training, the company is focused on ensuring the reliability of its technology, particularly as it prepares for clinical trials and seeks FDA clearance. The goal is to cover a wide range of conditions while maintaining rigorous safety protocols.
Walach also addressed concerns about AI's impact on radiologists' skills, advocating for a workflow that ensures human oversight. He believes that while AI can enhance diagnostic efficiency and accuracy, it is crucial to maintain professional engagement to prevent skill degradation. As Aidoc moves forward, it aims to build trust in AI-assisted diagnostics while prioritizing patient safety.